Skip to main content

AI assistant

Sign in to chat with this filing

The assistant answers questions, extracts KPIs, and summarises risk factors directly from the filing text.

IONIS PHARMACEUTICALS INC Director's Dealing 2024

Jan 18, 2024

30591_dirs_2024-01-18_ab198561-106e-47b2-bb14-2636f13d6614.zip

Director's Dealing

Open in viewer

Opens in your device viewer

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: IONIS PHARMACEUTICALS INC (IONS)
CIK: 0000874015
Period of Report: 2024-01-16

Reporting Person: Swayze Eric (EVP Research)

Non-Derivative Transactions

Date Security Code Shares Price A/D Holdings After Ownership
2024-01-16 Common Stock M 17069 $0.0 Acquired 49585 Direct
2024-01-17 Common Stock S 6296 $50.417 Disposed 43289 Direct
2024-01-16 Common Stock M 21 $0.0 Acquired 94 Indirect
2024-01-17 Common Stock S 9 $50.417 Disposed 85 Indirect

Derivative Transactions

Date Security Exercise Price Code Shares A/D Expiration Underlying Ownership
2024-01-16 Restricted Stock Unit $0.0 M 17069 Disposed Common Stock (17069) Direct
2024-01-16 Restricted Stock Unit $0.0 M 21 Disposed Common Stock (21) Indirect

Footnotes

F1: Acquired pursuant to vesting and release of shares in accordance with Restricted Stock Unit awards.

F2: The sale was made pursuant to an automatic sale to cover the required tax withholding obligations pursuant to the 2011 Equity Incentive Plan Restricted Stock Unit Agreement and Grant Notice.

F3: The price reported in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $50.35 to $50.43, inclusive. The reporting person undertakes to provide to Ionis
Pharmaceuticals, Inc., any security holder of Ionis Pharmaceuticals, Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (3) of this Form 4.

F4: Acquired pursuant to vesting and release of shares in accordance with a Restricted Stock Unit award.

F5: Each Restricted Stock Unit represents a contingent right to receive one share of Ionis common stock, or its equivalent cash value.

F6: Restricted Stock Units vest in four equal annual installments. Upon vesting, the restricted stock units will be paid out in whole shares of Ionis common stock or cash as may be determined by the Company.